Jie Tong (捷通)捷通
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 浙江莎普爱思药业股份有限公司Chinese legal name: 浙江莎普爱思药业股份有限公司
主要成分Active Ingredients
- 乌拉地尔Wula Dier
药物知识说明
乌拉地尔是一种在国家药监局注册认定的药品。该药品含有乌拉地尔-1227c239等成分。
该药品关联的活性成分包括：乌拉地尔Wula Dier。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：浙江莎普爱思药业股份有限公司Chinese legal name: 浙江莎普爱思药业股份有限公司。
您可以探索含有相同成分的其他药品：乌拉地尔-1227c239成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 捷通) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 乌拉地尔Wula Dier.
Manufacturers recorded for this product: 浙江莎普爱思药业股份有限公司Chinese legal name: 浙江莎普爱思药业股份有限公司.
Explore other medicines containing the same ingredient: 乌拉地尔 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 捷通Recorded Chinese name: 捷通
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 100ml：乌拉地尔50mg与葡萄糖5g。Recorded Chinese description: 100ml：乌拉地尔50mg与葡萄糖5g。
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 浙江莎普爱思药业股份有限公司Chinese legal name: 浙江莎普爱思药业股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20041110
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20041110
Manufacturer
Chinese legal name: 浙江莎普爱思药业股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20041110
生产企业
浙江莎普爱思药业股份有限公司(国产)
适应症
用于治疗高血压危象（如血压急剧升高），重度和极重度高血压，以及难治性高血压。用于控制围手术期高血压。适用于静脉注射乌拉地尔后的维持治疗。
用法用量
本品为大输液制剂，适用于静脉注射乌拉地尔后的维持治疗。应先予乌拉地尔注射液静脉注射：缓慢静注10～50mg，监测血压变化，降压效果应在5分钟内即可显示。若效果不够满意，可重复用药。在静脉注射乌拉地尔后，予本品持续静脉点滴以维持降压作用。应根据病人的血压调整给药速度，推荐初始速度为2mg/min，维持速度为9mg/h（输注本品时，1mg乌拉地尔相当于44滴或2.2ml输入液）。血压下降的程度由前15分钟内输入的药物剂量决定，然后用低剂量维持。疗程一般不超过7天。
不良反应
尚不明确。
禁忌
禁用于对本品成分过敏的患者。主动脉峡部狭窄或动静脉分流的患者禁用（肾透析时的分流除外）。哺乳期妇女禁用。
贮藏
密闭、遮光、阴凉处保存
规格
100ml：乌拉地尔50mg与葡萄糖5g。
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.